Gilteritinib Superior in Relapsed, Refractory FLT3-Mutated AML

THURSDAY, Oct. 31, 2019 -- For relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 gene (FLT3), treatment with a selective FLT3 inhibitor, gilteritinib, results in significantly longer survival and a...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news